Literature DB >> 9924887

Early detection of anthracycline-induced cardiotoxicity by radionuclide angiocardiography.

J Suzuki1, A Yanagisawa, T Shigeyama, J Tsubota, T Yasumura, K Shimoyama, K Ishikawa.   

Abstract

For the early detection of myocardial damage associated with anthracycline therapy, electrocardiography, echocardiography, and radionuclide angiocardiography were used to assess cardiac function in 37 patients receiving anthracyclines (ie, adriamycin and daunorubicin at a total dose of 100-2,030 mg/m2). None of the patients developed clinical congestive heart failure. There were no significant changes of electrocardiographic and echocardiographic parameters after anthracycline administration. The left ventricular ejection fraction did not change significantly on radionuclide angiocardiography. However, the 1/3 peak filling rate (PFR) corrected by the end-diastolic count (EDC) (1/3 PFR/EDC) and the 1/3 filling fraction (1/3 FF), the indices of early diastolic function, showed a significant decrease. These findings suggest that the 1/3 PFR/EDC and 1/3 FF determined by radionuclide imaging are useful for detecting silent myocardial damage induced by anthracyclines.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9924887     DOI: 10.1177/000331979905000105

Source DB:  PubMed          Journal:  Angiology        ISSN: 0003-3197            Impact factor:   3.619


  10 in total

1.  Evaluation of epirubicin-induced cardiotoxicity by two-dimensional strain echocardiography in breast cancer patients.

Authors:  Xiaojun Bi; Youbin Deng; Fanjing Zeng; Ying Zhu; Yuhan Wu; Ceyao Zhao; Chunlei Li
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-06-10

2.  Usefulness of myocardial performance index in multiple sclerosis mitoxantrone-induced cardiotoxicity.

Authors:  Paolo Pattoneri; Giovanna Pelà; Enrico Montanari; Ilaria Pesci; Paolo Moruzzi; Alberto Montanari
Journal:  Heart Asia       Date:  2012-01-01

3.  Mitochondrials complex I activity is reduced in latent adriamycin-induced cardiomyopathy of rat.

Authors:  Kiyotaka Ohkura; Jong-Dae Lee; Hiromasa Shimizu; Akira Nakano; Hiroyasu Uzui; Motosaburo Horikoshi; Yasuhisa Fujibayashi; Yoshiharu Yonekura; Takanori Ueda
Journal:  Mol Cell Biochem       Date:  2003-06       Impact factor: 3.396

4.  Cardiac toxicity of high-dose cyclophosphamide in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation.

Authors:  Samo Zver; Vesna Zadnik; Matjaz Bunc; Polona Rogel; Peter Cernelc; Mirta Kozelj
Journal:  Int J Hematol       Date:  2007-06       Impact factor: 2.490

5.  Cardiac toxicity of high-dose cyclophosphamide and melphalan in patients with multiple myeloma treated with tandem autologous hematopoietic stem cell transplantation.

Authors:  Samo Zver; Vesna Zadnik; Peter Černelč; Mirta Koželj
Journal:  Int J Hematol       Date:  2008-06-12       Impact factor: 2.490

6.  Systolic versus diastolic cardiac function variables during epirubicin treatment for breast cancer.

Authors:  Jon M Appel; Benny V Jensen; Dorte L Nielsen; Marianne Ryberg; Bo Zerahn
Journal:  Int J Cardiovasc Imaging       Date:  2009-10-13       Impact factor: 2.357

Review 7.  Cardiotoxicity of concomitant radiotherapy and trastuzumab for early breast cancer.

Authors:  Tanja Marinko; Jure Dolenc; Cvetka Bilban-Jakopin
Journal:  Radiol Oncol       Date:  2014-04-25       Impact factor: 2.991

8.  Does diastolic dysfunction precede systolic dysfunction in trastuzumab-induced cardiotoxicity? Assessment with multigated radionuclide angiography (MUGA).

Authors:  E J Reuvekamp; B F Bulten; A A Nieuwenhuis; M R A Meekes; A F J de Haan; J Tol; A H E M Maas; S E Elias-Smale; L F de Geus-Oei
Journal:  J Nucl Cardiol       Date:  2015-06-06       Impact factor: 5.952

9.  Matters of the heart: cardiac toxicity of adjuvant systemic therapy for early-stage breast cancer.

Authors:  K Towns; P L Bedard; S Verma
Journal:  Curr Oncol       Date:  2008-01       Impact factor: 3.677

10.  Early Cardiotoxicity after Adjuvant Concomitant Treatment with Radiotherapy and Trastuzumab in Patients with Breast Cancer.

Authors:  Tanja Marinko; Simona Borstnar; Rok Blagus; Jure Dolenc; Cvetka Bilban-Jakopin
Journal:  Radiol Oncol       Date:  2018-02-25       Impact factor: 4.214

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.